Hook & thesis
Exelixis is caught between two forces: a resilient commercial franchise and a binary clinical calendar. The stock sits at $55.28 with a market capitalization near $13.7 billion, supported by solid free cash flow, but near-term upside is limited until the STELLAR-304 dataset in H2 2026 clarifies zanzalintinib's positioning. Reports of a subpopulation miss for zanzalintinib have introduced measurable uncertainty; until we have the full STELLAR-304 readout, the prudent stance is Hold.
This is a risk-managing Hold, not a hard Sell. Fundamentals justify a buy-and-hold case over a multiyear horizon, but for the next several weeks to months the clinical binary dominates price action. We lay out a disciplined plan for holders and prospective entrants: if you own EXEL, size positions conservatively and avoid adding into clinical noise; if you want exposure, use a tactical starter entry with a tight stop and clearly defined targets tied to clinical updates.
What Exelixis does and why the market should care
Exelixis is an oncology company focused on discovering, developing and commercializing therapies for difficult-to-treat cancers. Its marketed assets include Cabometyx, and it has been advancing zanzalintinib as a next-generation targeted therapy. Cabometyx remains a meaningful cash engine, but the market is looking to the pipeline - particularly zanzalintinib - to extend growth beyond the current product lifecycle.
Fundamentals in a snapshot
- Current price: $55.28.
- Market cap: ~$13.7 billion.
- Trailing EPS: $3.47 and trailing P/E roughly in the mid-teens (reported ~15.7x).
- Enterprise value: ~$13.26 billion with EV/EBITDA ~13.0x and EV/sales ~5.4x.
- Free cash flow: ~$1.17 billion (most recent reported), supporting R&D and potential business development.
- 52-week range: $33.76 - $57.57.
The numbers show a company that generates meaningful cash and trades at reasonable multiples for an oncology peer with a marketed franchise and late-stage pipeline candidates. That said, valuation today incorporates expectations for zanzalintinib's commercial potential; any hit to those expectations will translate to multiple compression.
Clinical backdrop - why STELLAR-304 matters
Zanzalintinib is central to the bull case: analysts and coverage note it could be a multibillion-dollar franchise if phase 3 results confirm broad benefit. There are public reports of a subpopulation miss for zanzalintinib which has created investor caution. Details on that signal are limited at the moment; the market is properly waiting for the complete STELLAR-304 readout in H2 2026 before re-pricing the opportunity.
Technical and market-flow context
- Daily technicals are constructive but not exuberant: 10-day SMA $54.92 and 50-day SMA $54.63, RSI ~54 — the tape is neutral-to-slightly-bullish around current levels.
- Short interest remains elevated: recent settlement shows ~28 million shares short with days-to-cover in the high single digits to low double digits (latest 8.7 days), indicating potential for short-term volatility around catalysts.
- Average daily volume runs around ~1.9 million shares (two-week average), giving the stock liquidity to move on clinical headlines.
Valuation framing
At a ~$13.7 billion market cap and EV roughly in the same area, Exelixis trades at mid-teens on a trailing earnings basis and EV/EBITDA near 13x. Those multiples are neither dirt-cheap nor frothy for a profitable oncology company with both a marketed product and late-stage assets. The implicit assumption baked into the price is that zanzalintinib will contribute meaningfully to growth; a materially negative STELLAR-304 readout would likely compress multiples, while a clean, positive readout would support multiple expansion or at least justify a re-rating toward premium oncology peers.
Catalysts to watch
- STELLAR-304 full readout - H2 2026: the primary binary that should determine near-term direction.
- Quarterly earnings and guidance cadence: the next release will update revenue traction and margin trends for Cabometyx.
- Regulatory/label updates for zanzalintinib across indications - incremental approvals or expanded labels would be materially positive.
- Business development: partnerships or licensing deals could de-risk commercialization and offer non-dilutive funding for launches.
Trade plan - Hold with a tactical optionality trade
Recommendation: Hold (Neutral). Existing holders: maintain positions but trim to reduce exposure to the H2 2026 data event if risk budget is limited. Prospective buyers: do not initiate a full-sized position ahead of STELLAR-304. For disciplined traders who want some exposure, use the trade below as a tactical, limited-size starter.
Actionable trade (tactical starter)
- Entry price: $50.00
- Stop loss: $46.00
- Target price: $65.00
- Trade size: 25% of your normal position size (this is a starter position to be added to after the STELLAR-304 readout if the result is positive).
- Horizon: mid term (45 trading days) - this covers the window for pre-readout positioning, the STELLAR-304 headline reaction and the near-term post-readout volatility. If the stock breaks higher on positive data, hold to the $65 target or reassess based on follow-up guidance and commercial assumptions. If the stock breaks below the stop, exit and wait for new information.
Rationale: a $50 entry gives a better risk/reward versus the current $55 level and buys room for post-data volatility. A $46 stop caps downside to a manageable level for a starter exposure; the $65 target reflects a re-rating toward growth expectations if zanzalintinib wins a clean readout and cadence of launches proceeds as modeled.
Risks and counterarguments
Below are the principal risks that justify a Hold instead of a Buy, followed by counterarguments to the Hold thesis.
- Clinical binary risk - The STELLAR-304 readout is binary and could materially change peak sales assumptions for zanzalintinib. A missed primary or meaningful subgroup signal would likely trigger downside beyond normal market churn.
- Subpopulation signal concerns - Early reports of a subpopulation miss have already injected uncertainty. If further analysis shows limited benefit in key biomarker-defined groups, commercial potential could shrink.
- Regulatory and label risk - Approval or label expansions depend on convincing data in specific populations. A narrower label would reduce peak revenue assumptions.
- Competition and lifecycle risk - Cabometyx, while a current revenue driver, faces eventual generic competition (commentators project generic pressure around the end of the decade). The company needs the pipeline to pick up the slack; any delay in launches or tepid uptake will pressure growth.
- Market sensitivity and short interest - Elevated short interest and active short-volume days increase the potential for outsized intraday moves on headline flow.
- Macroeconomic / valuation compression - If the broader market rotates away from growth-at-a-reasonable-price sectors, even a neutral readout could be met with muted reaction and multiple contraction.
Counterargument to the Hold thesis
There is a credible bull counter: Exelixis generates ~ $1.17 billion in free cash flow and trades at mid-teens multiples. The company already has a marketed product and zanzalintinib has prior regulatory momentum in at least one indication. If STELLAR-304 shows a clinically meaningful benefit, the stock could gap higher quickly as the market re-prices a multi-billion dollar opportunity. For investors with a longer time horizon who can stomach post-readout volatility, initiating a measured position prior to the readout could capture the upside if the data is clean.
What would change my view
I would move from Hold to Buy if the STELLAR-304 readout provides clear, statistically robust benefit across the intended population and management lays out concrete commercialization plans and uptake assumptions that materially increase zanzalintinib's probability-weighted peak sales. Conversely, I would move to Sell if the readout confirms the subpopulation miss and management indicates a significantly narrowed target population or delayed regulatory pathway.
Conclusion
Exelixis is a fundamentally sound oncology company with healthy cash generation and a realistic valuation for its mix of marketed products and late-stage assets. But the immediate price path is being driven by a binary clinical event. For most investors the prudent action is Hold: retain existing exposure, avoid material additions ahead of STELLAR-304, and consider a small tactical starter at $50 with a $46 stop and $65 target if you want to participate while limiting downside. The next major data release should meaningfully reduce uncertainty and create a clearer risk/reward for a larger position.
Key dates & monitoring checklist
- Monitor company communications and the full STELLAR-304 dataset in H2 2026 for survival and subgroup breakdowns.
- Watch quarterly results for Cabometyx trends and any updated guidance or commentary on launch sequencing.
- Track short-interest cycles and volume spikes around clinical news to manage trade execution risk.
If you hold EXEL today, this is a time to be vigilant rather than aggressive. Wait for data clarity before committing more capital.